Compare · QS vs TMO
QS vs TMO
Side-by-side comparison of QuantumScape Corporation (QS) and Thermo Fisher Scientific Inc (TMO): market cap, price performance, sector, and recent activity on the wire.
Summary
- QS operates in Miscellaneous, while TMO operates in Industrials - the two are in different parts of the market.
- TMO is the larger of the two at $175.70B, about 28.8x QS ($6.09B).
- Over the past year, QS is up 76.5% and TMO is up 14.9% - QS leads by 61.6 points.
- QS has been more active in the news (19 items in the past 4 weeks vs 17 for TMO).
- TMO has more recent analyst coverage (25 ratings vs 22 for QS).
- Company
- QuantumScape Corporation
- Thermo Fisher Scientific Inc
- Price
- $7.66+0.00%
- $469.56-0.67%
- Market cap
- $6.09B
- $175.70B
- 1M return
- +4.08%
- -1.03%
- 1Y return
- +76.50%
- +14.92%
- Industry
- Industrial Machinery/Components
- Industrial Machinery/Components
- Exchange
- NYSE
- NYSE
- IPO
- News (4w)
- 19
- 17
- Recent ratings
- 22
- 25
QuantumScape Corporation
QuantumScape Corporation, a development stage company, engages in the development and commercialization of solid-state lithium-metal batteries for electric vehicles and other applications. The company was founded in 2010 and is headquartered in San Jose, California.
Thermo Fisher Scientific Inc
Thermo Fisher Scientific Inc. offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; ImmunoCAP for allergy and asthma tests, and EliA for autoimmunity tests; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Services segment provides laboratory refrigerators and freezers, ultralow-temperature freezers, and cryopreservation storage tanks; temperature control, sample preparation and preservation, centrifugation, and biological safety cabinet products; water analysis instruments; laboratory plastics products; laboratory chemicals; and pharma services. The company offers products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors, and catalogs. It has a strategic alliance with the University of California, San Francisco. The company was incorporated in 1956 and is based in Waltham, Massachusetts.
Latest QS
- Director Saluja Dipender was granted 24,183 shares, increasing direct ownership by 6% to 396,418 units (SEC Form 4)
- Director Segers Dennis was granted 24,183 shares, increasing direct ownership by 19% to 149,524 units (SEC Form 4)
- Director Ribar Geoffrey G was granted 24,183 shares, increasing direct ownership by 67% to 60,285 units (SEC Form 4)
- Director Niebergall Ross was granted 24,183 shares, increasing direct ownership by 51% to 71,558 units (SEC Form 4)
- Director Hanley Jeneanne Michelle was granted 24,183 shares, increasing direct ownership by 17% to 165,729 units (SEC Form 4)
- Director Lovett Gena C was granted 24,183 shares, increasing direct ownership by 20% to 144,354 units (SEC Form 4)
- Director Buss Brad W was granted 24,183 shares, increasing direct ownership by 20% to 146,659 units (SEC Form 4)
- QuantumScape Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- CHIEF TECHNOLOGY OFFICER Holme Timothy converted options into 190,935 shares and sold $1,774,898 worth of shares (190,935 units at $9.30) as part of a pre-agreed trading plan (SEC Form 4)
- CHIEF FINANCIAL OFFICER Hettrich Kevin sold $78,977 worth of shares (9,800 units at $8.06) as part of a pre-agreed trading plan, decreasing direct ownership by 0.53% to 1,833,902 units (SEC Form 4)
Latest TMO
- Thermo Fisher downgraded by HSBC Securities with a new price target
- Wolfe Research resumed coverage on Thermo Fisher with a new price target
- SEC Form SD filed by Thermo Fisher Scientific Inc
- Thermo Fisher Scientific Unveils Next-generation Innovations at ASMS 2026 to Accelerate the Path from Drug Discovery to New Therapies
- Thermo Fisher Scientific Inc filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Director Weisler Dion J covered exercise/tax liability with 80 shares and was granted 499 shares, increasing direct ownership by 8% to 5,446 units (SEC Form 4)
- Director Sperling Scott M was granted 499 shares, increasing direct ownership by 0.72% to 69,479 units (SEC Form 4)
- Director Spar Debora L was granted 499 shares, increasing direct ownership by 24% to 2,610 units (SEC Form 4)
- Director Lynch Karen S was granted 499 shares, increasing direct ownership by 76% to 1,159 units (SEC Form 4)
- Director Keith R. Alexandra was granted 499 shares, increasing direct ownership by 24% to 2,602 units (SEC Form 4)